Is Relay Therapeutics a Buy After Promising Trial Results?
Relay had its initial public offering in 2020. The company's lead therapy is being tested for the treatment of vascular disorders and cancers.
RLAY - Relay Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$23.00
DETAILS
HIGH:
$27.00
LOW:
$18.00
MEDIAN:
$22.00
CONSENSUS:
$23.00
UPSIDE:
69.99%
Stock News
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. , May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.00 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additional 3,437,500 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $275 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Relay Therapeutics.
Why Relay Therapeutics Stock Popped on Wednesday
This was aided by a pair of bullish analyst updates. The two pundits raised their price targets and maintained their buy ratings.
Relay Therapeutics: Zovegalisib Is Becoming A Platform In Disguise
Relay Therapeutics is undervalued as the market overlooks its potential to build a multi-indication PI3Kα inhibitor franchise beyond breast cancer. Zovegalisib's Breakthrough Therapy designation and strong Phase 3 data support its differentiated tolerability and efficacy profile, targeting both oncology and vascular anomalies. RLAY's $642M cash position, recent ATM raise, and cost controls provide runway into 2029, enabling pivotal trials and pipeline expansion without near-term financing risk.
Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies Transcript
Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies Transcript
Relay Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today that it has commenced an underwritten public offering of $175 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Relay Therapeutics.
Relay's treatment shown to shrink vascular malformations in mid-stage trial
Relay Therapeutics said on Tuesday a mid-stage trial showed its experimental treatment can shrink vascular malformations and improve symptoms in patients with rare vascular disorders.
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates
Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.46 per share a year ago.
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer
Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways
Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA decision, and 2026 is stacked with catalysts.
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report first quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Tuesday, May 5, 2026.
Relay Therapeutics, Inc. (RLAY) Discusses Zovegalisib Triplet Data and First-Line Breast Cancer Strategy Transcript
Relay Therapeutics, Inc. (RLAY) Discusses Zovegalisib Triplet Data and First-Line Breast Cancer Strategy Transcript
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated, CDK4/6-experienced patients (median third-line); ORR is similar across kinase and non-kinase PIK3CA mutations Phase 3 frontline trial in endocrine sensitive patients expected to initiate in early 2027, subject to regulatory feedback Supply agreement in place with Pfizer to supply atirmociclib for the Phase 3 frontline trial Relay Therapeutics to host a conference call today, April 27, at 8:30am ET CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced plans to move zovegalisib + atirmociclib, Pfizer's investigational, potential first-in-class CDK4 inhibitor, into Phase 3 development for frontline patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.
JPMorgan Chase & Co. Reduces Position in Relay Therapeutics, Inc. $RLAY
JPMorgan Chase and Co. cut its holdings in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) by 89.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 462,379 shares of the company's stock after selling 3,876,024 shares during the period. JPMorgan
Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?
Relay Therapeutics (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
SG Americas Securities LLC Acquires 189,004 Shares of Relay Therapeutics, Inc. $RLAY
SG Americas Securities LLC increased its holdings in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) by 591.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 220,949 shares of the company's stock after purchasing an additional 189,004 shares during the period. SG
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Relay Therapeutics, Inc. (NASDAQ: RLAY - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has assigned a strong buy
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that initial clinical results and preclinical data for zovegalisib (RLY-2608) in vascular anomalies will be presented at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026, taking place May 19-22, 2026, in Philadelphia. The company anticipates reporting clinical data on approximately 20 efficacy-evaluable patients.
Price Targets
Relay Therapeutics price target raised to $27 from $21 at Barclays
$27.00
(was $12.07)
Barclays
Relay Therapeutics price target raised to $26 from $23 at Raymond James
$26.00
(was $12.88)
UBS
Relay Therapeutics price target raised to $25 from $19 at H.C. Wainwright
$25.00
(was $13.03)
H.C. Wainwright
Relay Therapeutics price target raised to $18 from $14 at Oppenheimer
$18.00
(was $14.95)
Oppenheimer
Relay Therapeutics price target raised to $21 from $17 at Wells Fargo
$21.00
(was $14.95)
Wells Fargo
Relay Therapeutics price target raised to $22 from $13 at Goldman Sachs
$22.00
(was $14.95)
Salveen Richter
·
Goldman Sachs
Relay Therapeutics (RLAY) PT Raised to $22 at Guggenheim
$22.00
(was $10.81)
Brad Canino
·
Guggenheim
Relay Therapeutics upgraded to Outperform from Perform at Oppenheimer
$14.00
(was $7.43)
Oppenheimer
Relay Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
$13.00
(was $7.80)
Wells Fargo
Relay Therapeutics (RLAY) PT Raised to $19 at H.C. Wainwright
$19.00
(was $7.60)
Robert Burns
·
H.C. Wainwright
Relay Therapeutics upgraded to Buy from Hold at Jefferies
$16.00
(was $9.51)
Akash Tewari
·
Jefferies
Relay Therapeutics price target raised to $17 from $14 at Barclays
$17.00
(was $9.51)
Peter Lawson
·
Barclays
Relay Therapeutics (RLAY) PT Lowered to $20 at BofA Securities
$20.00
(was $6.41)
Jason Gerberry
·
Bank of America Securities
Barclays Upgrades Relay Therapeutics (RLAY) to Overweight
$15.00
(was $6.68)
Peter Lawson
·
Barclays
Relay Therapeutics (RLAY) PT Lowered to $25 at Oppenheimer
$25.00
(was $7.04)
Matt Biegler
·
Oppenheimer
Jefferies Upgrades Relay Therapeutics (RLAY ) to Hold
$12.50
(was $12.35)
Akash Tewari
·
Jefferies
Oppenheimer Initiates Coverage On Relay Therapeutics with Outperform Rating, Announces Price Target of $33
$33.00
(was $22.76)
Oppenheimer
Relay Therapeutics initiated with an Equal Weight at Barclays
$23.00
(was $23.14)
Peter Lawson
·
Barclays